Merck: Japan approves Lynparza to treat three cancers

(CercleFinance.com) - Merck said on Monday that the Japanese health authorities have approved Lynparza to treat three different cancers with specitic genetic abnormalities, enabling the US drugmaker to advance further on the market for personalized medicine.


The targeted treatment, which is being jointly developed and commercialised with Anglo-Swedish peer AstraZeneca, has been approved to treat advanced ovarian, prostate and pancreatic cancers, the company said in a statement.

Based on biomarker testing on diagnosis, the drug blocks DNA damage and helps doctors to determine a treatment tailored to individual patients, thereby delaying disease progression.

It has already been used by over 40,000 patients worldwide.

Copyright (c) 2020 CercleFinance.com. All rights reserved.